)
)
)
Phoremost
PhoreMost is a Cambridge UK-based biotechnology company dedicated to turning scientific breakthroughs into life-changing cancer therapies. The company has a number of disclosed alliances with partners, including Roche and Boehringer Ingelheim.
PMC-001 | Phase-1 ready candidate drug positioned to treat cancers with brain metastasis
PMC-002 | Novel synthetic lethal target for treatment of HPV+ cancers
PMC-003 | Degrader driven by novel ligase to overcome limitations of pan-BRD4i
TPD Platform | ‘Beyond Cereblon’ chemical ligase platform(s) for protein-of-interest degradation and pipeline expansion
The company is seeking to speak with investors to enable funding of PMC-001 through Phase1a & 1b clinical studies in addition to progressing pipeline assets to inflection points.
PhoreMost is also happy to explore potential partnerships with Pharma on its proprietary novel ligase platforms in addition to PMC-002 & PMC-003 assets.
Address
CambridgeshireUnited Kingdom
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)